Developing breakthrough AXL therapeutics to improve patients' lives

Developing breakthrough AXL therapeutics to improve patients' lives
Learn About Us
Background
DecorationDecoration

Information about the Warrants

Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

BerGenBio ASA: Last day of trading in warrants

BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue

BerGenBio ASA: Commencement of the last exercise period for warrants issued in connection with rights issue

BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025

BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue

BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation

BerGenBio to Participate in Carnegie Nordic Healthcare Seminar

BerGenBio ASA – Approval and publication of a prospectus supplement

BerGenBio’s Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum